BBH vs BIB
VanEck Biotech ETF against ProShares Ultra NASDAQ Biotechnology: cost, size, returns, what they hold and how much of it is the same.
Overlap by weight
35%
19 shared positions
Fee gap
60 bp
BBH is cheaper
1-year return gap
26.9 pts
BIB is ahead
Larger fund
BBH
$507M
Side by side
| BBH | BIB | |
|---|---|---|
| Fund | VanEck Biotech ETF | ProShares Ultra NASDAQ Biotechnology |
| Issuer | VanEck | ProShares |
| Category | Biotech & Health Innovation | Leveraged Equity |
| Expense ratio | 0.35% | 0.95% |
| Assets | $507M | $96M |
| Average daily dollar volume | $2.5M | $842K |
| Listed | Dec 20, 2011 | Apr 6, 2010 |
| FrenzyCap score | 63 | 44 |
| 1-month return | +3.5% | −2.1% |
| 3-month return | +22.8% | +15.8% |
| Year to date | +32.3% | +43.8% |
| 1-year return | +39.8% | +66.7% |
| 30-day volatility | 23.8% | 50.7% |
| Worst drawdown, 1 year | −10.5% | −17.9% |
| Trailing 12-month yield | 0.38% | 0.20% |
| Holdings | 27 | 256 |
| Top 10 weight | 73.1% | 157.8% |
| Look-through P/E | 79.4 | — |
| Holdings vs fair value | −2.9% | +3.4% |
| Holdings above 200-day average | 92% | 78% |
| Net flow, latest 3 reported months | −$5.5M thru Jun 2026 | −$14M thru May 2026 |
| 30-day implied volatility | 23.2% | 49.1% |
| Holdings as of | as of Oct 20, 2026issuer data | as of Oct 21, 2026issuer data |
Returns are price returns and exclude distributions. Flows are each fund's own latest reported months and may not cover the same period.
Largest shared holdings
86% of BBH · 35% of BIB
Sector mix of the stock holdings
| Sector | BBH | BIB | Gap |
|---|---|---|---|
| Health Care | 95.1% | 58.3% | +36.8% |
| Technology | 4.8% | 2.6% | +2.2% |
| Materials | 0.0% | 0.0% | −0.0% |
More: full overlap table · BBH holdings · BIB holdings
Fund data comes from each fund's SEC filings and issuer disclosures and is shown with the date it is as of. SEC portfolio and flow filings become public about 60 days after the period they cover. Nothing here is investment advice; see Terms.